FOCU.SE – The Swedish national collaborative group for the implementation of comprehensive genetic profiling in patients with advanced cancer
January 27, 2026 @ 09:00 – 09:40 CET
The programme includes a 40-minute talk followed by a 20-minute Q&A session
Biography
Edvard Abel, MD, PhD, is a consultant in oncology at the Dep of Oncology at Sahlgrenska Comprehensive Cancer Center in Gothenburg. He holds the position of Centre Director at Sahlgrenska CCC, as well as Medical Lead of the Phase I/First-in-Human trial unit at the Dep of Oncology. Dr Abel is the clinical principal investigator of the coming FOCU.SE trial, a national collaboration between Genomic Medicine Sweden, SciLifeLab and the oncological trial units, among others.
Abstract
The FOCU.SE trial platform provides a nationwide clinical infrastructure for the implementation of PCM in Sweden. By enabling biomarker-guided use of approved drugs within a structured clinical trial framework and supporting systematic evaluation of clinical outcomes, the platform aims to accelerate equitable access to personalised cancer therapy across healthcare regions. In parallel, it generates high-quality real-world evidence to support regulatory decision-making and potential expansion of indications for targeted therapies
Google Calendar 
iCalendar 
